The FDA has approved Flow Neuroscience’s FL-100, the first prescription at-home brain-stimulation device for major depressive disorder, bringing supervised tDCS into US clinical care.

Alto Neuroscience has raised $50 million and aligned with the FDA to accelerate its depression program, positioning biomarker-guided patient selection as a practical tool for late-stage psychiatric drug development.

Non-invasive brain stimulation has existed for decades, but its application to women’s cognitive health has lagged behind. A new neurotech venture is adapting tDCS to address menstrual-related cognitive and emotional symptoms.

Cities concentrate opportunity, but also stressors that subtly shape how we think, feel, and cope. From social fragmentation to pollution and light exposure, urban environments leave measurable traces on mental health.